Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON A versus SONAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON A versus SONAZINE.
ETRAFON-A vs SONAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON-A is a combination of perphenazine (a typical antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks dopamine D2 receptors, while amitriptyline inhibits serotonin and norepinephrine reuptake.
Sonazine is an antipsychotic agent that blocks postsynaptic dopamine D2 receptors in the mesolimbic system, with additional antagonist activity at D1, alpha1-adrenergic, histaminergic H1, and muscarinic M1 receptors.
Etrafon-A (perphenazine 4 mg/amitriptyline 10 mg) is not FDA-approved; typical dosing per manufacturer: 1 tablet 3-4 times daily, up to 4 tablets/day. Route: oral.
10-20 mg intramuscularly or intravenously every 4-6 hours as needed; maximum 100 mg/day.
None Documented
None Documented
Terminal elimination half-life: 18-36 hours (mean 24 h); context: in elderly or hepatic impairment may extend beyond 48 h, requiring dose adjustment.
Terminal elimination half-life: 24-36 hours; clinical context: allows once-daily dosing, steady state achieved in 5-7 days, prolongation in elderly or hepatic impairment
Renal: 50-60% as unchanged drug and metabolites (primarily glucuronide conjugates); Biliary/Fecal: 30-40%; up to 10% excreted via sweat/saliva.
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via biliary elimination)
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic